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Background: For patients with well-controlled asthma, ‘step down’ of therapy is recommended. We
evaluated Japanese patients switching from inhaled corticosteroid (ICS)/long-acting beta2-agonists
(LABA; equivalent to ﬂuticasone propionate [FP]/salmeterol [SAL] 250/50 mg twice daily [BD]) to ﬂuti-
casone furoate (FF)/vilanterol (VI) 100/25 mg, then stepping down to ICS alone.
Methods: This phase III trial had two treatment periods (P): P1, patients with well-controlled asthma on
FP/SAL 250/50 mg BD equivalent stepped across to once daily (OD) FF/VI 100/25 mg (open-label, eight
weeks); P2, patients remaining ‘well controlled’ after P1 stepped down to FF 100 mg OD/FP 100 mg BD/FP
250 mg BD (randomized 1:1:1, double-blind, 12 weeks). Co-primary P2 endpoints: percentage of patients
with well-controlled asthma; time to withdrawal due to poorly controlled asthma requiring step-up
therapy. Adverse events (AEs) were monitored.
Results: At the end of P1 (n ¼ 430), 373 (90.5%; 95% conﬁdence interval 87.29e93.18) patients' asthma
remained well controlled with FF/VI; in P2 (n ¼ 371), control was maintained in 89.5% (FF 100 mg)/79.5%
(FP 100 mg)/83.8% (FP 250 mg) of patients. In P2, 4.9e7.3% of patients were withdrawn due to worsening
asthma (time-to-withdrawal cumulative incidence curves were comparable). AEs were reported by 37%
of patients during P1; and by 36% (FF 100 mg)/48% (FP 100 mg)/49% (FP 250 mg) of patients in P2.
Conclusions: For patients with well-controlled asthma on mid dose ICS/LABA (equivalent to FP/SAL 250/
50 mg BD), control can be maintained when they are stepped across to FF/VI 100/25 mg OD. FF 100 mg OD
is an effective step-down therapy from FF/VI 100/25 mg OD with similar efﬁcacy to FP 100 mg BD and FP
250 mg BD.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Asthma affects more than 240million people worldwide, and its
prevalence has increased by more than 30% over the last decades
[1]. Japan has one of the highest asthma prevalence rates within
Asia [2], with approximately one million people affected [3]. One of
the key goals for asthma therapy is to maintain control and to
reduce the risk of further exacerbations. Inhaled corticosteroids
(ICS) are commonly used to control the symptoms of asthma,ishimura).
Ltd. This is an open access article uimprove lung function and quality of life, and reduce asthma
mortality [4,5].
ICS in common use are often administered twice daily (BD);
ﬂuticasone propionate (FP) is one example. However, adherence to
BD ICS regimens can be poor; contributing to lack of asthma control
[4]. Treatment compliance may be improved with the use of once-
daily (OD) regimens for patients with mild-to-moderate asthma
[6,7].
Current asthma guidelines recommend the use of a step-wise
approach to asthma management, whereby patients whose
asthma is poorly controlled may be ‘stepped up’ to receive
increased ICS dosage and/or additional therapies (such as long-
acting beta2 agonists [LABAs]) as necessary [4,5]. For patientsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
ACT Asthma Control Test™
AE adverse event
AESI AE of special interest
ANCOVA analysis of covariance
BD twice daily
CI conﬁdence interval
FEV1 forced expiratory volume in one second
FF ﬂuticasone furoate
FP ﬂuticasone propionate
ICS inhaled corticosteroid
ITT intent-to-treat population
LABA long-acting beta2-agonists
MedDRA Medical Dictionary for Regulatory Activities
NHANES National Health and Nutrition Examination Survey
OD once daily
PEF peak expiratory ﬂow
P period
SAE serious AE
SAL salmeterol
VI vilanterol
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therapy is ‘stepped down’, to reduce the risk of treatment-related
complications [4,5]. There is limited evidence for the best strat-
egy to step down asthma medication for patients on ICS/LABAwith
stable, well-controlled asthma [8].
The ICS ﬂuticasone furoate (FF), administered using the
ELLIPTA® dry powder inhaler, is a once-daily maintenance treat-
ment for adult and adolescent (12 years) patients with asthma
[9]. FF has an enhanced glucocorticoid receptor binding afﬁnity and
prolonged pharmacokinetic activity, compared with other corti-
costeroids [10]. In a phase IIb study, FF 50e200 mg given OD in the
evening demonstrated dose-related efﬁcacy in patients with
persistent asthma [11]. A further study of FP 100 mg BD and FF 50 mg
OD in patients with mild-to-moderate persistent asthma showed
that FP 100 mg BD improved the primary endpoint of evening
trough forced expiratory volume in one second (FEV1), compared
with placebo, whereas FF 50 mg OD did not demonstrate a signiﬁ-
cant effect [12]. Based on this, FF 100 mg OD is considered to be the
lowest effective FF dose for adult/adolescent asthma patients. FF
100 mg OD has also been identiﬁed as an effective mid-strength ICS
with similar efﬁcacy to that seen with FP 250 mg BD [13]. Thus FP
100 mg BD can be considered a low-to-mid strength ICS. Two FF
doses (100 mg or 200 mg) are approved as maintenance therapy in
the United States of America [9] and a number of other countries;
FF is also approved in combination with vilanterol (VI), an inhaled,
OD, LABA [14e16]. It is important to provide information on step-
down options for patients receiving FF/VI 100/25 mg therapy,
particularly for those countries where FF monotherapy is not
available.
This study aimed to clarify the role of FF 100 mg OD as step-
down therapy from FF/VI 100/25 mg OD, in comparison with FP
100 mg BD or FP 250 mg BD, in Japanese patients with well-
controlled asthma; however, the study was not powered to
detect treatment differences. An additional aim of the study was to
assess the impact on maintenance of asthma control when pa-
tients with well-controlled asthma on ICS/LABA equivalent to
FP/salmeterol (SAL) 250/50 mg BD were stepped across to FF/VI
100/25 mg OD.2. Materials and methods
This phase III trial (GSK: 201135; ClinicalTrials.gov:
NCT02094937) was a randomized, multicenter, double-blind, par-
allel-group study conducted in Japanese patients with asthma. The
study had two periods of treatment: ﬁrstly (Period 1), stepping
patients with well-controlled asthma across from their usual BD
ICS/LABA medication (dose equivalent to FP/SAL 250/50 mg BD) to
FF/VI 100/25 mg OD; secondly (Period 2), stepping down patients
with well-controlled asthma from FF/VI 100/25 mg OD to FF 100 mg
OD, FP 100 mg BD or FP 250 mg BD. The study was conducted in
accordance with Good Clinical Practice guidelines and the Decla-
ration of Helsinki [17]. The study protocol was approved by an
Institutional Review Board/Independent Ethics Committee. The
study was conducted between March 2014 and August 2015 across
33 centers in Japan (the trial protocol is available at http://www.
gsk-clinicalstudyregister.com/).
2.1. Patients
All patients had a current asthma diagnosis (as deﬁned by the
National Institutes of Health [18] at least one year prior to their ﬁrst
clinic visit) and provided written, informed consent.
Inclusion criteria included: age 18 years; stable asthma, as
judged by the investigator (deﬁned as no change in asthma medi-
cation for 8 weeks prior to the ﬁrst clinic visit and an Asthma
Control Test [ACT™] score of 20 at their ﬁrst clinic visit); use of
ICS/LABA (dose equivalent to FP/SAL 250/50 mg BD) for 12 weeks
prior to the ﬁrst clinic visit (registration), and the ability to avoid
salbutamol use for 6 h prior to clinic visits. Patients had to
demonstrate a best pre-bronchodilator FEV1 of 80% of the pre-
dicted normal value at their ﬁrst clinic visit. Predicted values were
based on the National Health and Nutrition Examination Survey
(NHANES) III, with an adjustment of 0.88 for Asian ethnicity [19].
The short-acting beta2 agonist salbutamol was provided at the ﬁrst
clinic visit andwas used as rescuemedication throughout the study.
Patients were excluded if they had experienced: a life-
threatening asthma episode within the last 10 years; an exacerba-
tion that required systemic corticosteroids within 12 weeks or that
resulted in hospitalization within 6 months of the ﬁrst clinic visit;
or a respiratory infection that was not resolved within 8 weeks of
the ﬁrst clinic visit. Patientswith evidence of concurrent respiratory
disease or other clinically signiﬁcant uncontrolled disease were
excluded. Current smokers and those with a smoking history of
10 pack years and those who had used inhaled tobacco products
within the 3 months prior to the ﬁrst clinic visit were excluded.
Patients were also excluded if they had used any investigational
drug within 30 days or ﬁve half-lives of the ﬁrst clinic visit, or
were taking any concomitant medication that would signiﬁcantly
alter the course of asthma or interact with the study drugs.
2.2. Study design
The study design included two treatment periods over a total
duration of 25 weeks, and is illustrated in Supplementary Fig. 1.
Eligible patients entered a 4-week run-in period, duringwhich time
they continued their usual ICS/LABAmedication (dose equivalent to
FP/SAL 250/50 mg BD). At the second clinic visit, patients with well-
controlled asthma were enrolled into Period 1. The deﬁnition of
well-controlled asthma is provided in Table 1.
During Period 1, which was an open-label treatment period of 8
weeks' duration, patients with well-controlled asthma were step-
ped across from ICS/LABA (equivalent to a dose of FP/SAL 250/50 mg
BD) to open-label FF/VI 100/25 mg OD. After Period 1, at clinic visit 5,
patients who continued to have well-controlled asthma were
Table 1
Deﬁnitions of asthma control used in the study.
Criteria Well-controlled asthma Poorly controlled asthma (requires step-up therapy)
Assessed in the week prior to clinic visits 2, 5 and 11 Assessed in each week prior to clinic visits 2e11
Both of the following should
be met:
Either of the following should
be met:
Asthma symptom score (daytime)a,b Score 1 on 1 day 2 of these 3 criteria Score 1 on 2 days 3 of these 5 criteria
Rescue medication (salbutamol) useb On 1 day On 2 days
Morning PEFb 80% of the best effort-value
every day
<80% of the best effort-value on
1 day
A best-effort pre-bronchodilator FEV1c 80% of predicted normal All of these 3 criteria <80% of predicted normal
Asthma symptom score (night-time)d,e Score of 0 Score 1
Asthma worsening/exacerbatione No Yes This criterion
FEV1, forced expiratory volume in one second; PEF, peak expiratory ﬂow.
a Daytime asthma symptom score (recorded for each day in the evening, before taking any rescue or study medication and before PEF measurement): 0, no symptoms; 1,
symptoms for one short period; 2, symptoms for two or more short periods; 3, symptoms for most of the day that did not affect the patient's normal daily activities; 4,
symptoms for most of the day that did affect the patient's normal daily activities; 5, symptoms so severe that the patient could not go to work or perform normal daily
activities.
b Assessed weekly.
c Assessed at clinic visits.
d Night-time asthma symptom score (recorded for each night in the morning, before taking any rescue or study medication and before PEF measurement): 0, no symptoms;
1, symptoms causing the patient to wake once (or wake early); 2, symptoms causing the patient to wake two or more times (including waking early); 3, symptoms causing the
patient to be awake for most of the night; 4, symptoms so severe that the patient did not sleep at all.
e Assessed daily.
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step-down options, for a treatment duration of 12 weeks: FF
100 mg OD; FP 100 mg BD; or FP 250 mg BD. Randomization was
performed centrally via an interactive voice response system. There
was a 1-week follow-up period following completion of (or early
withdrawal from) Period 2.
Protocol-deﬁned criteria for stopping treatment included:
pregnancy; detection of clinically relevant abnormal liver chemis-
try; occurrence of an adverse event (AE) making study continuation
difﬁcult; protocol deviation; and poor asthma control requiring
step-up treatment between clinic visits 2e11. The deﬁnition of
poorly controlled asthma requiring step-up treatment is provided
in Table 1. Additionally, patients who did not meet the strict deﬁ-
nition of well-controlled asthma at clinic visit 5 were deemed to
have met protocol-deﬁned stopping criteria.
2.3. Study endpoints
The co-primary endpoints were: time to withdrawal due to
poorly controlled asthma that required step-up treatment (as
deﬁned in Table 1) in Period 2; and the proportion of patients with
well-controlled asthma (as deﬁned in Table 1) in the last week of
Period 2.
Secondary endpoints for Period 2 included: mean change from
baseline in trough (pre-dose) FEV1, morning and evening peak
expiratory ﬂow (PEF [measured by the patient using an electronic
Peak Flow Meter and automatically recorded in electronic diaries]),
the proportion of symptom- and rescue medication-free 24-hour
periods, the ACT score, and the proportion of patients with an ACT
score20 at the end of the period. The statistical modelling used for
these assessments is described below. The same endpoints were
also assessed for Period 1 (also protocol-deﬁned as ‘other’ end-
points), including the time to withdrawal due to poorly controlled
asthma that required step-up treatment and the proportion of pa-
tients with well-controlled asthma (as deﬁned in Table 1).
AEs, serious AEs (SAEs), and AEs of special interest (AESIs) were
recorded throughout the study period and coded using the Medical
Dictionary for Regulatory Activities (MedDRA; version 18.0). AESIs
were deﬁned using pre-selected preferred terms (for Period 1:adrenal suppression, asthma/bronchospasm, cardiovascular effects,
corticosteroid-associated eye disorders, decreased bone mineral
density and associated fractures, effects on glucose, effects on po-
tassium, hypersensitivity, local steroid effects, lower respiratory
tract infections excluding pneumonia, pneumonia and tremor; for
Period 2: adrenal suppression, corticosteroid-associated eye dis-
orders, decreased bone mineral density and associated fractures,
effects on glucose, hypersensitivity, local steroid effects, lower
respiratory tract infections excluding pneumonia, and pneumonia).
2.4. Statistical analysis
This was a descriptive study. As the study was not powered to
detect treatment differences no formal statistical hypothesis testing
was performed for any of the endpoints. Although no formal
inference was planned, statistical models were used to estimate
mean differences between randomized treatment groups. In three
previous studies where patients with well-controlled asthma on
FP/SAL were stepped down to FP alone; during the 16 weeks after
step down from FP/SAL 100/50 mg BD to FP 100 mg BD, 16% of pa-
tients [20] and 21% of patients [21] withdrew due to worsening of
asthma with FP 100 mg BD, and 14.5% (n ¼ 34/234) of patients had
asthma not “well-controlled” during the 12 weeks after step down
from FP/SAL 250/50 mg BD to FP 250 mg BD [22]. Moreover, previous
studies with an FF 100 mg OD arm demonstrated withdrawal rates
due to lack of efﬁcacy ranging from 2e13%. Therefore in the current
study an approximate withdrawal rate of 5e20% due to poorly
controlled asthma (requiring step-up therapy) was assumed; it was
estimated that randomization of 360 patients across all three
treatment arms in Period 2 (with 120 patients per group), would
detect 18e72 withdrawals due to poorly controlled asthma
(requiring step-up therapy).
Time to withdrawal, due to poorly controlled asthma that
required step-up therapy, was analyzed using a Cox proportional
hazards regression model, which included terms for baseline pre-
dose FEV1 (measured at randomization), gender, age and treat-
ment. The probability of withdrawal, due to poorly controlled
asthma that required step-up therapy, was estimated for each by
treatment group using the Cox proportional hazards regression
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conﬁdence intervals [CIs] were estimated from the model.
The percentage of patients with well-controlled asthma was
analyzed using a logistic regressionmodel, which included terms for
baseline pre-dose FEV1 (measured at randomization), gender, age
and treatment. Treatment differences (expressed as odds ratios) and
95% CIs were estimated from the model. Premature withdrawals
prior to week 20 (clinic visit 11) for reasons other than asthma
exacerbation were excluded from the analysis of well-controlled
asthma in Period 2; all patients remaining in the study at week 20
were included in the analysis, regardless ofwhether or not therewas
sufﬁcient data for their asthma control to be evaluable. Similarly, in
Period 1, withdrawals prior to week 8 (clinic visit 5) for reasons
other than asthma exacerbation were excluded from the analysis of
well-controlled asthma; all patients remaining in the study at week
8 were included in the analysis, regardless of whether or not there
were sufﬁcient data for their asthma control to be evaluated.
Summary statistics were calculated for each treatment group for
changes from baseline in the secondary endpoints and statistical
analyses were performed using an analysis of covariance (ANCOVA)
model, which assessed baseline, gender, age and treatment.
For all endpoints, summary statistics were calculated for
changes from baseline in all patients treated with FF/VI 100/25 mg
OD at each clinic visit during Period 1.
2.5. Post-hoc analysis
An additional post-hoc analysis of asthma control was carried
out, excluding patients with any unevaluable data, as mentioned
above. This used the same analysis method as described above for
the percentage of patients with well-controlled asthma, butTable 2
Patient demographics and characteristics for Period 1 and Period 2.
Characteristic Period 1
FF/VI 100/25 mg OD (n ¼
Age, years Mean (SD) 48.1 (14.11)
Median 46.0
Minemax 18e82
Gender, n (%) Female 261 (61)
Male 169 (39)
Japanese ethnicity, n (%) 430 (100)
Duration of asthma (years), n (%) >0 to <1 0
1 to <5 117 (27)
5 to <10 109 (25)
10 to <15 46 (11)
15 to <20 36 (8)
20 to <25 31 (7)
25 to <30 22 (5)
30 to <35 25 (6)
35 44 (10)
Smoking history, n (%) Never smoked 329 (77)
Current smoker 0
Former smoker 101 (23)
ACT score at baseline, n (%) <20 1 (<1)a
20 2 (<1)a
21 8 (2)a
22 13 (3)a
23 38 (9)a
24 75 (17)a
25 293 (68)a
FEV1 at screening, mean (SD) Predicted pre-dose FEV1, % 105.88 (13.133)
Pre-SAL FEV1, L 2.781 (0.7773)
FEV1 at baseline, mean (SD) Predicted pre-dose FEV1, % 105.06 (12.957)a
Pre-dose FEV1, L 2.761 (0.7745)a
ACT, Asthma Control Test; BD, twice daily; FEV1, forced expiratory volume in one second
SD, standard deviation; VI, vilanterol.
a Baseline is deﬁned as pre-treatment at clinic visit 2 (week 0) for Period 1.
b Baseline is deﬁned as pre-treatment at clinic visit 5 (week 8) for Period 2.
c n ¼ 122.excluded patients with unevaluable data.
3. Results
3.1. Patients
In total, 551 patients were enrolled: 430 patients were included
in the Period 1 open-label population (and received 1 dose of
open-label study medication) and 371 patients were included in
the Period 2 intent-to-treat (ITT) population. The study was con-
ducted entirely in Japan and all patients were Japanese.
Baseline patient demographics and characteristics are provided
in Table 2; the treatment groups were well balanced. During the
run-in period, 77% of patients used FP/SAL and 21% of patients used
budesonide/formoterol fumarate dihydrate as ICS/LABA combina-
tion therapy.
The study ﬂow is illustrated in Fig. 1, including reasons for pa-
tient withdrawal. Of the 430 patients in Period 1, 86% (n ¼ 370)
completed the 8-week treatment period. The median time to
withdrawal due to poorly controlled asthma was 53 days (range
15e58). Reasons for withdrawal were: meeting the protocol-
deﬁned criteria for stopping treatment (10%); AEs (2%; n ¼ 9);
and lack of efﬁcacy, protocol deviation, investigator discretion, and
withdrawn consent (all <1%).
3.2. Efﬁcacy
3.2.1. Proportion of patients with well-controlled asthma in period
1 and period 2
The proportion of patients with well-controlled asthma at the
end of Period 2 (a co-primary endpoint), was 89.5% (n¼ 102/114) inPeriod 2
430) FF 100 mg OD (n ¼ 123) FP 100 mg BD (n ¼ 124) FP 250 mg BD (n ¼ 124)
47.1 (13.04) 46.8 (14.57) 48.9 (14.21)
45.0 44.0 48.0
19e73 21e80 18e77
68 (55) 74 (60) 73 (59)
55 (45) 50 (40) 51 (41)
123 (100) 124 (100) 124 (100)
0 0 0
40 (33) 26 (21) 32 (26)
27 (22) 40 (32) 26 (21)
15 (12) 16 (13) 9 (7)
10 (8) 11 (9) 13 (10)
5 (4) 12 (10) 10 (8)
10 (8) 5 (4) 4 (3)
5 (4) 7 (6) 9 (7)
11 (9) 7 (6) 21 (17)
91 (74) 93 (75) 97 (78)
0 0 0
32 (26) 31 (25) 27 (22)
1 (<1)b 0b 0b
1 (<1)b 0b 0b
2 (2)b 0b 4 (3)b
2 (2)b 2 (2)b 2 (2)b
12 (10)b 9 (7)b 5 (4)b
15 (12)b 13 (10)b 17 (14)b
90 (73)b 100 (81)b 96 (77)b
107.09 (12.138) 105.67 (13.608) 105.11 (13.853)
2.919 (0.7705) 2.784 (0.7616) 2.754 (0.8286)
106.79 (12.118)b,c 104.10 (12.584)b 104.43 (14.057)b
2.921 (0.7951)b,c 2.749 (0.7602)b 2.733 (0.8141)b
; FF, ﬂuticasone furoate; FP, ﬂuticasone propionate; OD, once daily; SAL, salbutamol;
Fig. 1. Patient disposition. BD, twice daily; FF, ﬂuticasone furoate; FP, ﬂuticasone propionate; OD, once daily. 1Withdrawn for Period 1 includes patients who were assessed as having
poor asthma control at week 8 (clinic visit 5). 2One patient was randomized incorrectly even though the patient was not eligible for randomization (reached protocol-deﬁned
stopping criteria in Period 1). 3Withdrawn for Period 2 includes patients who were assessed as having poor asthma control at week 20 (clinic visit 11). 4The patient who was
randomized even though the patient was not eligible for randomization (reached protocol-deﬁned stopping criteria in Period 1) is not included.
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group and 83.8% (n ¼ 98/117) in the FP 250 mg BD group (Table 3;
Supplementary Fig. 2). The odds ratio of having well-controlled
asthma was 1.75 (95% CI, 0.81, 3.78) for the FF 100 mg OD group
compared with the FP 100 mg BD group, and 1.37 (95% CI, 0.62, 3.04)
for the FF 100 mg OD group compared with the FP 250 mg BD group
(Table 3). It should be noted that this study was not powered to
detect treatment differences. Furthermore, this analysis includedTable 3
Withdrawal due to poorly controlled asthma requiring step-up therapy, and the proport
Perio
FF/V
(n ¼
Withdrawal due to poorly controlled asthma requiring step-up therapya
n 430
Withdrawalsb, n
(% [95% CI])
17
Probability of withdrawing by the end of 12 weeks' treatment in Period 2, % N/A
Comparison of FF 100 mg OD to FP dose in Period 2,
HR (95% CI)
N/A
Proportion of patients with well-controlled asthma at the end of each treatment
ne 412
Well controlled, n
(% [95% CI])
373
(90.5
Total not assessed as well controlled, n (%) 39 (9
Not controlled 29
Unevaluable 10
Comparison of FF 100 mg OD to FP dose in Period 2, OR of having well-controlled
asthma (95% CI)
N/A
BD, twice daily; CI, conﬁdence interval; FF, ﬂuticasone furoate; FP, ﬂuticasone propionate
a Analyzed for Period 2 using a Cox proportional hazards regression model including
b Withdrawn due to poorly controlled asthma requiring step-up therapy.
c Calculated using exact binomial distribution.
d Analyzed using a logistic regression model including terms for baseline pre-dose FE
e Patients withdrawn prior to clinic visit 5 (Period 1)/prior to clinic visit 11 (Period 2)all patients who attended clinic visit 11 regardless of whether or
not they had sufﬁcient evaluable data, as well as patients whowere
withdrawn from the study due to asthma exacerbation (deﬁned as
asthma ‘not controlled’) during Period 2.
A post-hoc analysis of asthma control in Period 2 was conducted,
excluding patients with any unevaluable asthma-control data (due
to incomplete electronic diary entries: n¼ 3, FF 100 mg OD; n¼ 8, FP
100 mg BD; n ¼ 3, FP 250 mg BD) at the end of Period 2 (Table 3).ion of patients with well-controlled asthma at the end of each treatment period.
d 1 Period 2
I 100/25 mg OD
430)
FF 100 mg OD
(n ¼ 123)
FP 100 mg BD
(n ¼ 124)
FP 250 mg BD
(n ¼ 124)
123 124 124
6
(4.9 [1.81, 10.32])c
7
(5.6 [2.30, 11.29])c
9
(7.3 [3.37, 13.33])c
3.8 5.2 6.0
N/A 1.16 (0.39, 3.47) 0.92 (0.32, 2.62)
periodd
114 117 117
[87.29, 93.18])
102
(89.5 [82.33,
94.44])c
93
(79.5 [71.03,
86.39])c
98
(83.8 [75.81,
89.93])c
.5) 12 (10.5) 24 (20.5) 19 (16.2)
9 16 16
3 8 3
N/A 1.75
(0.81, 3.78)
1.37
(0.62, 3.04)
; HR, hazard ratio; N/A, not applicable; OD, once daily; OR, odds ratio; VI, vilanterol.
terms for pre-dose FEV1 measured at randomization, sex, age and treatment.
V1, sex, age and treatment group for Period 2.
for reasons other than asthma exacerbation were excluded.
Fig. 2. Cumulative incidence analysis of time to withdrawal due to poorly controlled
asthma for Period 2 (ITT population). BD, twice daily; FF, ﬂuticasone furoate; FP, ﬂu-
ticasone propionate; ITT, intent-to-treat; OD, once daily.
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the proportion of patients with well-controlled asthma between
the ICS treatment groups: 91.9% of patients (n¼ 102/111), FF 100 mg
OD; 85.3% of patients (n ¼ 93/109), FP 100 mg BD; and 86.0% of
patients (n ¼ 98/114), FP 250 mg BD.
At the end of Period 1 (‘step across’ to FF/VI) asthma remained
well controlled by FF/VI 100/25 mg OD in 90.5% of patients (n¼ 373/
412; 95% CI, 87.29e93.18; Table 3). Of the 9.5% (n ¼ 39/412) of
patients whose asthmawas not considered to be well controlled, 10
patients were unevaluable and asthma was assessed as not
controlled in 29 patients (Table 3).3.2.2. Time to withdrawal due to poorly controlled asthma
requiring step-up therapy in period 2
By the end of Period 2, the proportion of patients withdrawn
due to poorly controlled asthma that required step-up treatment (a
co-primary endpoint), was 4.9% in the FF 100 mg OD group (n ¼ 6/
123), compared with 5.6% in the FP 100 mg BD group (n ¼ 7/124)
and 7.3% in the FP 250 mg BD group (n ¼ 9/124; Table 3). Analysis
using a Cox proportional hazards model showed no marked dif-
ference in time towithdrawal for FP 100 mg BD or 250 mg BD relative
to FF 100 mg OD (Fig. 2) and hazard ratios were close to unity for
both comparisons (Table 3).Table 4
Mean change from baseline in efﬁcacy endpoints at the end of each treatment period.
Efﬁcacy endpoint Period 1 P
FF/VI 100/25 mg OD (n ¼ 430) F
Mean change from baselinea
n 391 1
FEV1, L 0.001 (SD 0.1568) 
n 429 1
Morning PEFb, L/min 3.7 (SD 24.59) 
n 428 1
Evening PEFb, L/min 2.5 (SD 24.02) 
n 430 1
Symptom-free 24-hour periodsb, % 1.0 (SD 9.66) 
n 428 1
Rescue medication-free 24-hour periodsb, % 0.2 (SD 9.97) 
n 408 1
ACT score 0.1 (SD 1.66) 
ACT, asthma control test; BD, twice daily; FEV1, forced expiratory volume in one second; F
daily; SD, standard deviation; SE, standard error; VI, vilanterol.
a For Period 1, raw mean changes from baseline at clinic visit 5 are presented; for Perio
with effects due to baseline, sex, age and treatment.
b PEF values, the percentages of symptom-free 24-hour periods and the percentages o3.2.3. Other measures of efﬁcacy in period 1 and period 2
Lung function and ACT score remained stable throughout
treatment in Period 1, following the step across from mid-dose ICS/
LABA BD (FP/SAL 250/50 mg BD dose equivalent) to FF/VI 100/25 mg
OD. The proportions of rescue medication-free and symptom-free
24-hour periods also remained more than 95% during treatment
in Period 1 (Supplementary Fig. 3).
During Period 2, reductions from baseline were observed in
FEV1 and PEF for all three groups treated with ICS alone, while the
proportions of symptom-free and rescue medication-free 24-hour
periods and ACT scores remained relatively stable (Table 4,
Supplementary Fig. 4). Trough FEV1 declined by 105e135 mL (the
difference between FF 100 mg OD and FP 100 mg BD was 6 mL [95%
CI, e37, 49 mL] and the difference between FF 100 mg OD and FP
250 mg BDwas24mL [95% CI,e67,19mL]), and dailymorning PEF
declined by 18.1 to 21.3 L/minute (the daily evening PEF results
also followed this trend).
3.3. Safety
During the 8-week treatment in Period 1, AEs were reported by
37% of patients (n ¼ 161/430), drug-related AEs were reported by
2% of patients (n ¼ 9) and there were no SAEs or deaths (Table 5).
Nasopharyngitis was the only AE reported by 3% of patients. Oral
candidiasis, themost frequently reported drug-related AE, occurred
in <1% of patients (n ¼ 4). AEs that led to study discontinuation
occurred in 2% of patients (n ¼ 9); bronchitis and asthma were the
only AEs leading to withdrawal that were reported by more than
one patient. Local steroid effects (3%) and hypersensitivity (2%)
were the most commonly reported AESIs.
During the 12-week treatment duration of Period 2, fewer pa-
tients in the FF 100 mg OD group (36%; n ¼ 44/123) reported AEs
than in the FP 100 mg BD (48%; n ¼ 59/124) or FP 250 mg (49%;
n ¼ 61/124) BD groups (Table 5). The most frequently reported AE
in all groups was nasopharyngitis, and oral candidiasis was the
most frequently reported drug-related AE. Two SAEs were re-
ported: complete abortion by one patient in the FF 100 mg OD group
and fractured clavicle in the FP 250 mg BD group, neither was
considered to be related to treatment. No deaths were reported
during the study. AEs led to study withdrawal in two patients (2%)
in the FF 100 mg OD group, four patients (3%) in the FP 100 mg BD
group and one patient (<1%) in the FP 250 mg BD group. AESIs were
reported by 11% of patients (n¼ 14) in both the FF 100 mg OD and FPeriod 2
F 100 mg OD (n ¼ 123) FP 100 mg BD (n ¼ 124) FP 250 mg BD (n ¼ 124)
22 124 124
0.129 (SE 0.0158) 0.135 (SE 0.0154) 0.105 (SE 0.0155)
22 124 124
18.2 (SE 2.09) 21.3 (SE 2.06) 18.1 (SE 2.06)
22 124 124
19.2 (SE 2.04) 19.3 (SE 2.01) 18.7 (SE 2.02)
22 124 124
1.8 (SE 0.652)1.0 (SE 0.654) 1.3 (SE 0.653)
22 124 124
0.9 (SE 0.554) 2.1 (SE 0.553) 1.2 (SE 0.552)
22 124 124
0.3 (SE 0.225) 0.6 (SE 0.224) 0.8 (SE 0.223)
F, ﬂuticasone furoate; FP, ﬂuticasone propionate; PEF, peak expiratory ﬂow; OD, once
d 2, adjusted mean changes from baseline were calculated using an ANCOVA model
f rescue medication-free 24-hour periods were averaged over the treatment period.
Table 5
Adverse events reported for Period 1 and Period 2.
AE, n (%) Period 1 Period 2
FF/VI 100/25 mg OD (n ¼ 430) FF 100 mg OD (n ¼ 123) FP 100 mg BD (n ¼ 124) FP 250 mg BD (n ¼ 124)
Any AE 161 (37) 44 (36) 59 (48) 61 (49)
Drug-related AEs 9 (2) 5 (4) 5 (4) 3 (2)
AEs leading to treatment discontinuation 9 (2) 2 (2) 4 (3) 1 (<1)
AEs leading to dose interruption 1 (<1) 0 0 0
SAE 0 1 (<1) 0 1 (<1)
Deaths 0 0 0 0
AE preferred term, na (%)
Infections and infestations 102 (24) 32 (26) 38 (31) 43 (35)
Nasopharyngitis 67 (16) 22 (18) 22 (18) 28 (23)
Inﬂuenza 4 (<1) 3 (2) 5 (4) 4 (3)
Bronchitis 8 (2) 3 (2) 3 (2) 4 (3)
Oral candidiasis 5 (1) 5 (4) 1 (<1) 2 (2)
Pharyngitis 6 (1) 1 (<1) 3 (2) 4 (3)
Immune system disorders 4 (<1) 1 (<1) 4 (3) 1 (<1)
Seasonal allergy 3 (<1) 1 (<1) 4 (3) 1 (<1)
AE, adverse event; BD, twice daily; FF, ﬂuticasone furoate; FP, ﬂuticasone propionate; OD, once daily; SAE, serious adverse event; VI, vilanterol.
a Includes individual AEs that occurred at an incidence of 3% in any treatment group.
M. Adachi et al. / Respiratory Medicine 120 (2016) 78e8684100 mg BD groups, and 13% of patients (n ¼ 16) in the FP 250 mg BD
group. The most common AESIs were local steroid effects and hy-
persensitivity. Severe asthma exacerbation was observed in 2% of
patients in each of the three treatment groups.
4. Discussion
There is a lack of robust data from clinical trials to guide
healthcare practitioners as to whether asthma control is likely to be
maintainedwhen switching a patient from one ICS/LABA to another
or stepping down from an ICS/LABA to an ICS monotherapy. When
patients with well-controlled asthma have been stepped down
from FP/SAL to treatment with ICS alone, their asthma control
deteriorated [23,24]. The present study was designed to help
answer this question for patients with well-controlled asthma on
FF/VI 100/25 mg OD stepping down to ICS monotherapy.
During Period 1 of this study, when patients with well-
controlled asthma were stepped across from ICS/LABA (FP/SAL
250/50 mg BD dose equivalent) to FF/VI 100/25 mg OD, asthma
control was maintained in 90.5% of patients with no change seen in
other efﬁcacy measures, such as lung function and the proportions
of symptom-free and rescue medication-free 24-hour periods.
These results show that patients whose asthma is controlled with a
mid-dose ICS/LABA may be stepped across to FF/VI 100/25 mg OD
with the vast majority maintaining control.
In Period 2 of this study when patients with well-controlled
asthma were stepped down from FF/VI 100/25 mg OD to FF
100 mg OD, FP 100 mg BD or FP 250 mg BD, asthma control was
maintained for 12 weeks in approximately 80e90% of patients. In
addition, the proportion of patients who were withdrawn from the
study due to poorly controlled asthma requiring step-up treatment
was comparable across the three treatment groups with similar
time-to-withdrawal curves. FEV1 and PEF declined across all three
treatment groups; this was not surprising as LABAs are known to
improve lung function [25]. Despite the decline in lung function
with minimal change in symptom-free and rescue medication-free
days seen across the three treatment groups, asthma control was
maintained in 80e90% of patients. The ﬁnding that asthma control
was maintained, despite declining lung function, could be attrib-
uted to the fact that mean baseline FEV1 was greater than 104%
predicted in all treatment groups. Thus, evenwith the FEV1 decline
of 105e135 mL, the predicted FEV1 remained over 80% (the cut-off
point used to deﬁne ‘well-controlled asthma’ in this study).
Limited data are available from previous clinical studies tosupport the positioning of FF 100 mg OD amongst currently avail-
able ICS monotherapies. A previous study has shown the efﬁcacy of
FF 100 mg OD to be similar with FP 250 mg BD, both in terms of the
AE proﬁle and the effect on 24-hour urinary cortisol excretion, in
the treatment of patients with uncontrolled asthma [26]. The pre-
sent study has shown that in patients with well-controlled asthma
there is no dose response effect between FP 100 mg BD and FP
250 mg BD and, additionally, the efﬁcacy of FF 100 mg OD is similar to
both FP 100 mg BD and FP 250 mg BD across all endpoints assessed
(asthma control, lung function, symptoms and rescue medication
use).
The AE proﬁle of FF/VI 100/25 mg OD is well documented [27]
and no new safety ﬁndings were reported during this study. The
frequency of AEs reported for FF 100 mg OD was 12e13% lower than
for FP 100 mg BD and FP 250 mg BD. The safety proﬁle for FF 100 mg
OD was consistent with known ICS class effects [4], and the fre-
quency of the most common AEs (nasopharyngitis, inﬂuenza and
oral candidiasis) was comparable across treatment groups in Period
2 (FF 100 mg OD, FP 100 mg BD and FP 250 mg BD). Taken together
with the efﬁcacy results, our data indicate that all three ICS regi-
mens investigated in this study are appropriate step-down treat-
ments for patients with asthma that is well controlled with FF/VI
100/25 mg.
Strengths of the study included high levels of compliance with
completion of electronic diaries, which resulted in few patients
having unevaluable data at the end of each treatment period when
asthma control was evaluated. Another strength was the selection
of patients whomet the strict deﬁnition of asthma control. This was
the ﬁrst study to assess FF 100 mg OD relative to two strengths of FP.
These data support the use of FF 100 mg OD, FP 100 mg BD or FP
250 mg BD as appropriate step-down monotherapies for patients
whose asthma is well controlled as per the strict deﬁnition from the
Japanese asthma guidelines on FF/VI 100/25 mg OD.
One potential weakness of this study was that all patients who
remained in the study at week 12 were included in the analysis of
patients with well-controlled disease, whether or not control could
be evaluated. Since more patients had unevaluable data (due to
incomplete electronic diary entries) in the FP 100 mg BD group than
in the FF 100 mg OD group, this may confound the ﬁndings. How-
ever, a post-hoc analysis excluding these patients showed similar
ﬁndings to the pre-deﬁned endpoints, although the between-group
differences were smaller. Another limitation is that this study was
not formally powered to detect treatment differences; no formal
statistical hypothesis testing was performed for any of the
M. Adachi et al. / Respiratory Medicine 120 (2016) 78e86 85endpoints. Additionally, as the study was conducted entirely in
Japan, the applicability of the results to other ethnicities remains to
be determined. However, recent publications have suggested that
the efﬁcacy and safety of both FF/VI OD (and FF OD) and FP/SAL BD
(and FP BD) are of low ethnic sensitivity [28, 29].
In conclusion, patients can maintain well-controlled asthma
when stepped across from twice-daily ICS/LABA (equivalent to FP/
SAL 250/50 mg BD) to FF/VI 100/25 mg OD. Furthermore, FF 100 mg
OD is an appropriate treatment choice for adults with asthma who
require treatment with low- or mid-dose ICS, and it is an effective
step-down therapy from FF/VI 100/25 mg OD in those with well-
controlled asthma. Additionally, once-daily treatment of FF
100 mg may potentially improve adherence to ICS treatment.
However, where FFmonotherapy is not licensed, FP 100 mg BD or FP
250 mg BD are also appropriate step-down treatments for patients
whose asthma is well controlled on FF/VI 100/25 mg OD.
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